Stockscreener 앱 받기
51.07
0.22%
0.11
시장 영업 전:
52.99
1.92
+3.76%
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Citi Analyst Maintains Buy Rating on Protagonist Therapeutics with $72.00 Price Target - AInvest
Protagonist Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Florida Times-Union
Protagonist Therapeutics Completes Promising Phase 2 Study on PTG-300 for Polycythemia Vera - TipRanks
Protagonist Therapeutics’ Rusfertide Study: A Promising Update for Polycythemia Vera Treatment - TipRanks
Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability - TipRanks
Protagonist Therapeutics price target raised to $69 from $67 at Citizens JMP - TipRanks
Protagonist Therapeutics stock price target raised to $69 by JMP - Investing.com Canada
Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress - TipRanks
Protagonist (PTGX) Q2 Revenue Falls 26% - The Motley Fool
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
Protagonist Therapeutics: Promising Developments in Rusfertide and Icotrokinra Drive Buy Rating - TipRanks
Protagonist Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Canada
Why Protagonist Therapeutics Shares Are Dropping - TipRanks
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Protagonist Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Protagonist Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
Protagonist Therapeutics Q2 net loss beats expectations - MarketScreener
Protagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus - TipRanks
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - MSN
Why is Protagonist Therapeutics Inc. stock attracting strong analyst attentionStay ahead with daily expert stock picks - Jammu Links News
What drives Protagonist Therapeutics Inc. stock priceHigh-octane financial growth - Jammu Links News
Does Protagonist Therapeutics Inc. stock perform well during market downturnsFree Stock Index Interpretation - Jammu Links News
What is Protagonist Therapeutics Inc. company’s growth strategyRapid return acceleration - Jammu Links News
Is it the right time to buy Protagonist Therapeutics Inc. stockAchieve rapid wealth accumulation with smart picks - Jammu Links News
What is the dividend policy of Protagonist Therapeutics Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
Is Protagonist Therapeutics Inc. a growth stock or a value stockTremendous return on equity - Jammu Links News
What are the technical indicators suggesting about Protagonist Therapeutics Inc.Build wealth steadily with proven investment strategies - Jammu Links News
How does Protagonist Therapeutics Inc. compare to its industry peersHigh-octane investment gains - Jammu Links News
What catalysts could drive Protagonist Therapeutics Inc. stock higher in 2025Superior return velocity - Jammu Links News
How strong is Protagonist Therapeutics Inc. company’s balance sheetInvest confidently with professional market insights - Jammu Links News
Protagonist Therapeutics Inc. Stock Analysis and ForecastTriple-digit growth rates - Jammu Links News
What are analysts’ price targets for Protagonist Therapeutics Inc. in the next 12 monthsRapid wealth accumulation - Jammu Links News
How many analysts rate Protagonist Therapeutics Inc. as a “Buy”AI Powered Picks For Fast Growth - Jammu Links News
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Livingston Daily
What are the latest earnings results for Protagonist Therapeutics Inc.Free Stock Watchlist For Fast Growth - jammulinksnews.com
Protagonist Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayConservative Long Term Growth Plans Under Review - metal.it
Will Protagonist Therapeutics Inc. continue its uptrendAI Powered High Return Stock Calls Dominate Watchlists - metal.it
Protagonist Therapeutics Inc. Crosses 200 Day MA — Signal or NoiseHigh Return Stock Focus With Safety Emphasized - metal.it
Protagonist Therapeutics' CEO Insider Sale: Signal or Noise Amid Strong Analyst Optimism? - AInvest
Protagonist Therapeutics Inc. Hits Oversold Level on RSI IndicatorCapital Efficiency Optimized Stock Alerts Reviewed - metal.it
Screener Results Flag Protagonist Therapeutics Inc. as OversoldTarget Return Focused Trade Insights Shared - beatles.ru
Protagonist therapeutics CEO Patel sells $570k in stock By Investing.com - Investing.com Canada
Published on: 2025-07-28 20:33:17 - metal.it
Published on: 2025-07-28 15:35:31 - metal.it
How does Protagonist Therapeutics Inc. generate profit in a changing economyDiscover top stock picks for aggressive growth - Jammu Links News
What are Protagonist Therapeutics Inc. company’s key revenue driversDaily Trading Picks Backed By Experts - Jammu Links News
0.24%
3.39%
자본화:
|
볼륨(24시간):